Drug Development & Biomarkers in Rare CNS Diseases, AD/PD™ Session Spotlight

In this episode, we spotlight Forum Discussion 08 from the AD/PD™ 2025 International Conference — “Drug Development & Biomarkers in Rare CNS Diseases (ALS, FTD) from Basics to Approval – How to Define Success.”The discussion was moderated by Prof. Angela Genge (Canada) and Prof. Laura Ranum (USA), with expert contributions from Dr. Francesca Cignarella (USA), Prof. Guy Rouleau (Canada), Dr. Toby Ferguson (USA), and Prof. Patrick Weydt (Germany).Key highlights from this session include:• Advances in drug development for rare neurodegenerative diseases, with a focus on ALS and frontotemporal dementia (FTD)• Lessons learned from antisense oligonucleotide therapies, including SOD1-targeting approaches that have shown meaningful clinical impact in ALS• The growing importance of genetic stratification, enabling earlier and more targeted intervention in both symptomatic and presymptomatic individuals• How insights from related disorders, such as Huntington’s disease, are informing biomarker development, including the interpretation of neurofilament signals• The critical role of biomarkers in guiding clinical trials, measuring disease-relevant outcomes, and accelerating regulatory approval• The power of public–private partnerships, exemplified by initiatives such as the ALS Accelerating Medicines Partnership• The need for data sharing, collaboration, and patient involvement to overcome the challenges inherent in rare disease research• New infrastructure efforts, including the upcoming ALS Knowledge Platform, aimed at integrating data across studies to drive discoveryThe panel emphasized that success in rare CNS disease research requires not only scientific innovation, but also coordinated global collaboration, smarter trial design, and biomarkers that truly reflect disease biology. While challenges remain, the session conveyed strong optimism that genetics-driven approaches and shared data ecosystems will accelerate progress for ALS and FTD.This episode is particularly relevant for neurologists, translational researchers, clinical trialists, biotech and pharma professionals, patient advocacy leaders, and regulators working in rare neurodegenerative diseases.This podcast was created using AI to provide a concise and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to consult official conference materials for detailed information.The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders took place April 1–5, 2025, in Vienna, Austria.🔗 https://adpd.kenes.com